AIM4: Testing Dupilumab with Other Asthma Treatments
Trial Objectives
Researchers in the AIM4 study want to know if dupilumab, an injectable medication, when used alongside an inhaled asthma treatment, can help people with uncontrolled asthma reduce the frequency of their symptoms.
In this study, volunteers will be randomly assigned to either receive a combination of dupilumab and an inhaled asthma treatment, or a higher dose of the inhaled asthma medication. Researchers will compare the two treatment methods to help determine which one is more effective at reducing uncontrolled asthma symptoms.
At clinic visits, volunteers will receive physical examinations, lung function tests, and symptom assessments. They also will provide information on their symptom exacerbations over time.
Who Can Participate
Adults 18 to 80 with a diagnosis of asthma who are currently using an ICS and LABA asthma inhaler.
Age: 18-80 Gender: Any
Estimated Time Commitment
9 clinic visits over approximately 58 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Cynthia Wainscoat
303.398.1259
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Regeneron
Principal Investigators
Rohit K. Katial, MD